아이큐어

175250KOSDAQ

41.0 / 100

Reference Date: 2026-10-23

Financial Score16.5 / 40

News Sentiment12.5 / 25

Momentum2.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Plunged 15.8% over the past month, with no recent news.

Company InformationBased on 2025 Annual Report

Business Overview

IQure, established in 2000, specializes in developing transdermal drug delivery systems (TDDS) and pharmaceutical patches, along with OEM/ODM cosmetics. Following the successful Phase III trial of its donepezil patch in 2021, the company has secured global licensing agreements with pharmaceutical giants like Menarini and Celltrion. It also operates an ISO-certified cosmetics manufacturing facility, focusing on skincare OEM/ODM.

Number of Employees

286people

Average Salary

10.7M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 15.004.0Point

PBR

3.55Industry Average 1.200.0Point

3.0x industry avg (risky)

ROE

-82.73Industry Average 8.000.0Point

Well below industry avg

Debt Ratio

30.72Industry Average 100.006.5Point

Half of industry avg (excellent)

Trend 2023~20256.0 / 10 points

Revenue Growth Rate

3.0 / 3

Avg ▲21.2% (2-year basis)

Operating Profit Growth Rate

3.0 / 3

Avg ▲27.3% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -41.8% (declining, 3yr)

Detailed News Sentiment

0 totalPositive 0Neutral 0Negative 0

Detailed Momentum

52-week position1.0Point

Near 52w low (0%, downtrend)

Current 1,405Won52-week high 2,17052-week low 1,405

1-month return0.0Point

1m -15.77% (strong drop)

Volume trend1.0Point

Volume decreasing

Detailed Disclosure

5 totalPositive 0Neutral 5Negative 0

Neutral[기재정정]반기보고서 (2026.06)2026-10-20
Neutral[기재정정]반기보고서 (2026.06)2026-10-20
Neutral[기재정정]주식등의대량보유상황보고서(일반)2026-10-07
Neutral주식등의대량보유상황보고서(일반)2026-10-07
Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-09-30